Biodegradable stents for the treatment of refractory or recurrent benign esophageal stenosis

被引:20
作者
Imaz-Iglesia, Inaki [1 ]
Garcia-Perez, Sonia [1 ]
Nachtnebel, Anna [2 ]
Martin-Agueda, Belen [3 ]
Sanchez-Piedra, Carlos [4 ]
Karadayi, Bilgehan [5 ]
Demirbas, Ali Riza [5 ]
机构
[1] Inst Salud Carlos III, AETS, 5 Monforte de Lemos, Madrid 28029, Spain
[2] Ludwig Boltzmann Inst Hlth Technol Assessment, Vienna, Austria
[3] Hlth Minist Hlth, Profess Regulat, Madrid, Spain
[4] Spanish Rheumatol Sci Soc, Res Unit, Madrid, Spain
[5] Minist Hlth, SAGEM, Hlth Res, Ankara, Turkey
关键词
Oesophagus obstruction; esophageal stenosis; stents; bioprosthesis; absorbable implants; esophageal dilatation; health technology assessment; STRICTURES; PLACEMENT;
D O I
10.1080/17434440.2016.1184967
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Introduction: Esophageal stents are used for the treatment of refractory and recurrent dyphagias. In 2007, esophageal biodegradable stents (EBS) were authorised as an alternative to existing metal and plastic stents in Europe. The advantages claimed for EBS are fewer complications concerning tissue ingrowth, stent migration and stent removal.Areas covered: We performed a systematic review to evaluate the efficacy and safety of EBS compared to fully-covered self-expanding metal stents, self-expanding plastic stents, and esophageal dilation for the treatment of refractory or recurrent benign esophageal stenosis. Three comparative studies (one randomized controlled trial and two cohort studies) were assessed. The studies used different inclusion criteria, had a very small (sample) size and the quality of the evidence was very low.Expert commentary: The current evidence is insufficient to determine the relative efficacy or safety of esophageal biodegradable stents. The results of this systematic review should be updated once new evidence is available.
引用
收藏
页码:583 / 599
页数:17
相关论文
共 22 条
[1]  
[Anonymous], 2015, THER MED DEV
[2]  
Cook Jonathan A, 2004, Clin Trials, V1, P421, DOI 10.1191/1740774504cn042oa
[3]   Open access publishing takes off - The dream is now achievable [J].
Delamothe, T ;
Smith, R .
BMJ-BRITISH MEDICAL JOURNAL, 2004, 328 (7430) :1-3
[4]   Biodegradable stent or balloon dilatation for benign oesophageal stricture: Pilot randomised controlled trial [J].
Dhar, Anjan ;
Close, Helen ;
Viswanath, Yirupaiahgari K. ;
Rees, Colin J. ;
Hancock, Helen C. ;
Dwarakanath, A. Deepak ;
Maier, Rebecca H. ;
Wilson, Douglas ;
Mason, James M. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (48) :18199-18206
[5]   Surgical Innovation and Evaluation 2 Challenges in evaluating surgical innovation [J].
Ergina, Patrick L. ;
Cook, Jonathan A. ;
Blazeby, Jane M. ;
Boutron, Isabelle ;
Clavien, Pierre-Alain ;
Reeves, Barnaby C. ;
Seiler, Christoph M. .
LANCET, 2009, 374 (9695) :1097-1104
[6]  
Heng B., 2014, ANN PALLIAT MED, V3, P41
[7]  
Higgins J.P.T., 2020, SURGERY, DOI DOI 10.1016/J.SURG.2009.06.030
[8]   Single and sequential biodegradable stent placement for refractory benign esophageal strictures: a prospective follow-up study [J].
Hirdes, M. M. C. ;
Siersema, P. D. ;
van Boeckel, P. G. A. ;
Vleggaar, F. P. .
ENDOSCOPY, 2012, 44 (07) :649-654
[9]   Refractory and the recurrent esophageal stricture: a definition [J].
Kochman, ML ;
McClave, SA ;
Boyce, HW .
GASTROINTESTINAL ENDOSCOPY, 2005, 62 (03) :474-475
[10]   OMEPRAZOLE VERSUS H2-RECEPTOR ANTAGONISTS IN TREATING PATIENTS WITH PEPTIC STRICTURE AND ESOPHAGITIS [J].
MARKS, RD ;
RICHTER, JE ;
RIZZO, J ;
KOEHLER, RE ;
SPENNEY, JG ;
MILLS, TP ;
CHAMPION, G .
GASTROENTEROLOGY, 1994, 106 (04) :907-915